0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Opioid-Induced Constipation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027
Published Date: July 2021
|
Report Code: QYRE-Auto-716
Home | Market Reports | Health | Pharmacy | Drugs & Medications
Global Opioid Induced Constipation Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027

Global Opioid-Induced Constipation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Code: QYRE-Auto-716
Report
July 2021
122 Pages
QYResearch
Region: Global, Europe, North America, Middle East, Asia Pacific,
Description
Table of Content
Tables & Figures
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Market Analysis and Insights: Global Opioid-Induced Constipation Market

In 2020, the global Opioid-Induced Constipation market size was US$ 2415 million and it is expected to reach US$ 3315 million by the end of 2027, with a CAGR of 4.6% during 2021-2027.

Global Opioid-Induced Constipation Scope and Market Size
Opioid-Induced Constipation market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Opioid-Induced Constipation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Opioid-Induced Constipation market is segmented into

Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others

Segment by Application, the Opioid-Induced Constipation market is segmented into

Hospital
Pharmacy
Other
Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape and Opioid-Induced Constipation Market Share Analysis
Opioid-Induced Constipation market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Opioid-Induced Constipation product introduction, recent developments, Opioid-Induced Constipation sales by region, type, application and by sales channel.
The major companies include:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
1 Study Coverage
1.1 Opioid-Induced Constipation Product Introduction
1.2 Market by Type
1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
2.1.1 Global Opioid-Induced Constipation Revenue 2016-2027
2.1.2 Global Opioid-Induced Constipation Sales 2016-2027
2.2 Opioid-Induced Constipation Market Size by Region: 2021 Versus 2027
2.3 Opioid-Induced Constipation Sales by Region (2016-2027)
2.3.1 Global Opioid-Induced Constipation Sales by Region: 2016-2021
2.3.2 Global Opioid-Induced Constipation Sales Forecast by Region (2022-2027)
2.3.3 Global Opioid-Induced Constipation Sales Market Share by Region (2016-2027)
2.4 Opioid-Induced Constipation Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Opioid-Induced Constipation Revenue by Region: 2016-2021
2.4.2 Global Opioid-Induced Constipation Revenue Forecast by Region (2022-2027)
2.4.3 Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2027)
3 Global Opioid-Induced Constipation by Manufacturers
3.1 Global Top Opioid-Induced Constipation Manufacturers by Sales
3.1.1 Global Opioid-Induced Constipation Sales by Manufacturer (2016-2021)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Opioid-Induced Constipation Manufacturers by Revenue
3.2.1 Global Opioid-Induced Constipation Revenue by Manufacturer (2016-2021)
3.2.2 Global Opioid-Induced Constipation Revenue Share by Manufacturer (2016-2021)
3.3 Global Opioid-Induced Constipation Price by Manufacturer (2016-2021)
3.4 Competitive Landscape
3.4.1 Key Opioid-Induced Constipation Manufacturers Covered: Ranking by Revenue
3.4.2 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI) & (2016-2021)
3.4.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Opioid-Induced Constipation Manufacturing Base Distribution, Product Type
3.5.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Opioid-Induced Constipation Product Type
3.5.3 Date of International Manufacturers Enter into Opioid-Induced Constipation Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Takeda Pharmaceuticals
4.1.1 Takeda Pharmaceuticals Corporation Information
4.1.2 Takeda Pharmaceuticals Description, Business Overview
4.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
4.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.1.5 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Product
4.1.6 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Application
4.1.7 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Geographic Area
4.1.8 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Sales Channel
4.1.9 Takeda Pharmaceuticals Recent Development
4.2 Bayer
4.2.1 Bayer Corporation Information
4.2.2 Bayer Description, Business Overview
4.2.3 Bayer Opioid-Induced Constipation Products Offered
4.2.4 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.2.5 Bayer Opioid-Induced Constipation Revenue by Product
4.2.6 Bayer Opioid-Induced Constipation Revenue by Application
4.2.7 Bayer Opioid-Induced Constipation Revenue by Geographic Area
4.2.8 Bayer Opioid-Induced Constipation Revenue by Sales Channel
4.2.9 Bayer Recent Development
4.3 Sanofi
4.3.1 Sanofi Corporation Information
4.3.2 Sanofi Description, Business Overview
4.3.3 Sanofi Opioid-Induced Constipation Products Offered
4.3.4 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.3.5 Sanofi Opioid-Induced Constipation Revenue by Product
4.3.6 Sanofi Opioid-Induced Constipation Revenue by Application
4.3.7 Sanofi Opioid-Induced Constipation Revenue by Geographic Area
4.3.8 Sanofi Opioid-Induced Constipation Revenue by Sales Channel
4.3.9 Sanofi Recent Development
4.4 Mallinckrodt
4.4.1 Mallinckrodt Corporation Information
4.4.2 Mallinckrodt Description, Business Overview
4.4.3 Mallinckrodt Opioid-Induced Constipation Products Offered
4.4.4 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.4.5 Mallinckrodt Opioid-Induced Constipation Revenue by Product
4.4.6 Mallinckrodt Opioid-Induced Constipation Revenue by Application
4.4.7 Mallinckrodt Opioid-Induced Constipation Revenue by Geographic Area
4.4.8 Mallinckrodt Opioid-Induced Constipation Revenue by Sales Channel
4.4.9 Mallinckrodt Recent Development
4.5 Salix (Bausch Health)
4.5.1 Salix (Bausch Health) Corporation Information
4.5.2 Salix (Bausch Health) Description, Business Overview
4.5.3 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
4.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.5.5 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Product
4.5.6 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Application
4.5.7 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Geographic Area
4.5.8 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Sales Channel
4.5.9 Salix (Bausch Health) Recent Development
4.6 AstraZeneca
4.6.1 AstraZeneca Corporation Information
4.6.2 AstraZeneca Description, Business Overview
4.6.3 AstraZeneca Opioid-Induced Constipation Products Offered
4.6.4 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.6.5 AstraZeneca Opioid-Induced Constipation Revenue by Product
4.6.6 AstraZeneca Opioid-Induced Constipation Revenue by Application
4.6.7 AstraZeneca Opioid-Induced Constipation Revenue by Geographic Area
4.6.8 AstraZeneca Recent Development
4.7 Progenics Pharmaceuticals
4.7.1 Progenics Pharmaceuticals Corporation Information
4.7.2 Progenics Pharmaceuticals Description, Business Overview
4.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
4.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.7.5 Progenics Pharmaceuticals Opioid-Induced Constipation Revenue by Product
4.7.6 Progenics Pharmaceuticals Opioid-Induced Constipation Revenue by Application
4.7.7 Progenics Pharmaceuticals Opioid-Induced Constipation Revenue by Geographic Area
4.7.8 Progenics Pharmaceuticals Recent Development
4.8 Purdue Pharm
4.8.1 Purdue Pharm Corporation Information
4.8.2 Purdue Pharm Description, Business Overview
4.8.3 Purdue Pharm Opioid-Induced Constipation Products Offered
4.8.4 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.8.5 Purdue Pharm Opioid-Induced Constipation Revenue by Product
4.8.6 Purdue Pharm Opioid-Induced Constipation Revenue by Application
4.8.7 Purdue Pharm Opioid-Induced Constipation Revenue by Geographic Area
4.8.8 Purdue Pharm Recent Development
4.9 Nektar Therapeutics
4.9.1 Nektar Therapeutics Corporation Information
4.9.2 Nektar Therapeutics Description, Business Overview
4.9.3 Nektar Therapeutics Opioid-Induced Constipation Products Offered
4.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.9.5 Nektar Therapeutics Opioid-Induced Constipation Revenue by Product
4.9.6 Nektar Therapeutics Opioid-Induced Constipation Revenue by Application
4.9.7 Nektar Therapeutics Opioid-Induced Constipation Revenue by Geographic Area
4.9.8 Nektar Therapeutics Recent Development
4.10 Daiichi Sankyo
4.10.1 Daiichi Sankyo Corporation Information
4.10.2 Daiichi Sankyo Description, Business Overview
4.10.3 Daiichi Sankyo Opioid-Induced Constipation Products Offered
4.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.10.5 Daiichi Sankyo Opioid-Induced Constipation Revenue by Product
4.10.6 Daiichi Sankyo Opioid-Induced Constipation Revenue by Application
4.10.7 Daiichi Sankyo Opioid-Induced Constipation Revenue by Geographic Area
4.10.8 Daiichi Sankyo Recent Development
4.11 Prestige
4.11.1 Prestige Corporation Information
4.11.2 Prestige Description, Business Overview
4.11.3 Prestige Opioid-Induced Constipation Products Offered
4.11.4 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.11.5 Prestige Opioid-Induced Constipation Revenue by Product
4.11.6 Prestige Opioid-Induced Constipation Revenue by Application
4.11.7 Prestige Opioid-Induced Constipation Revenue by Geographic Area
4.11.8 Prestige Recent Development
4.12 GSK
4.12.1 GSK Corporation Information
4.12.2 GSK Description, Business Overview
4.12.3 GSK Opioid-Induced Constipation Products Offered
4.12.4 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.12.5 GSK Opioid-Induced Constipation Revenue by Product
4.12.6 GSK Opioid-Induced Constipation Revenue by Application
4.12.7 GSK Opioid-Induced Constipation Revenue by Geographic Area
4.12.8 GSK Recent Development
4.13 Shionogi
4.13.1 Shionogi Corporation Information
4.13.2 Shionogi Description, Business Overview
4.13.3 Shionogi Opioid-Induced Constipation Products Offered
4.13.4 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
4.13.5 Shionogi Opioid-Induced Constipation Revenue by Product
4.13.6 Shionogi Opioid-Induced Constipation Revenue by Application
4.13.7 Shionogi Opioid-Induced Constipation Revenue by Geographic Area
4.13.8 Shionogi Recent Development
5 Breakdown Data by Type
5.1 Global Opioid-Induced Constipation Sales by Type (2016-2027)
5.1.1 Global Opioid-Induced Constipation Sales by Type (2016-2021)
5.1.2 Global Opioid-Induced Constipation Sales Forecast by Type (2022-2027)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2027)
5.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2016-2027)
5.2.1 Global Opioid-Induced Constipation Revenue by Type (2016-2021)
5.2.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2022-2027)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2027)
5.3 Opioid-Induced Constipation Average Selling Price (ASP) by Type (2016-2027)
6 Breakdown Data by Application
6.1 Global Opioid-Induced Constipation Sales by Application (2016-2027)
6.1.1 Global Opioid-Induced Constipation Sales by Application (2016-2021)
6.1.2 Global Opioid-Induced Constipation Sales Forecast by Application (2022-2027)
6.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2016-2027)
6.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2016-2027)
6.2.1 Global Opioid-Induced Constipation Revenue by Application (2016-2021)
6.2.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2022-2027)
6.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2027)
6.3 Opioid-Induced Constipation Average Selling Price (ASP) by Application (2016-2027)
7 North America
7.1 North America Opioid-Induced Constipation Market Size YoY Growth 2016-2027
7.2 North America Opioid-Induced Constipation Market Facts & Figures by Country
7.2.1 North America Opioid-Induced Constipation Sales by Country (2016-2027)
7.2.2 North America Opioid-Induced Constipation Revenue by Country (2016-2027)
7.3 North America Opioid-Induced Constipation Sales by Type
7.4 North America Opioid-Induced Constipation Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Opioid-Induced Constipation Market Size YoY Growth 2016-2027
8.2 Asia-Pacific Opioid-Induced Constipation Market Facts & Figures by Region
8.2.1 Asia-Pacific Opioid-Induced Constipation Sales by Region (2016-2027)
8.2.2 Asia-Pacific Opioid-Induced Constipation Revenue by Region (2016-2027)
8.3 Asia-Pacific Opioid-Induced Constipation Sales by Type
8.4 Asia-Pacific Opioid-Induced Constipation Sales by Application
9 Europe
9.1 Europe Opioid-Induced Constipation Market Size YoY Growth 2016-2027
9.2 Europe Opioid-Induced Constipation Market Facts & Figures by Country
9.2.1 Europe Opioid-Induced Constipation Sales by Country (2016-2027)
9.2.2 Europe Opioid-Induced Constipation Revenue by Country (2016-2027)
9.3 Europe Opioid-Induced Constipation Sales by Type
9.4 Europe Opioid-Induced Constipation Sales by Application
10 Latin America
10.1 Latin America Opioid-Induced Constipation Market Size YoY Growth 2016-2027
10.2 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
10.2.1 Latin America Opioid-Induced Constipation Sales by Country (2016-2027)
10.2.2 Latin America Opioid-Induced Constipation Revenue by Country (2016-2027)
10.3 Latin America Opioid-Induced Constipation Sales by Type
10.4 Latin America Opioid-Induced Constipation Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Opioid-Induced Constipation Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
11.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2027)
11.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2027)
11.3 Middle East and Africa Opioid-Induced Constipation Sales by Type
11.4 Middle East and Africa Opioid-Induced Constipation Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Opioid-Induced Constipation Supply Chain Analysis
12.2 Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers
12.3 Opioid-Induced Constipation Clients Analysis
12.4 Opioid-Induced Constipation Sales Channel and Sales Model Analysis
12.4.1 Opioid-Induced Constipation Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Opioid-Induced Constipation Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Opioid-Induced Constipation Distributors
13 Market Dynamics
13.1 Opioid-Induced Constipation Market Drivers
13.2 Opioid-Induced Constipation Market Opportunities
13.3 Opioid-Induced Constipation Market Challenges
13.4 Opioid-Induced Constipation Market Restraints
13.5 Porter’s Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type (US$ Million): 2021 VS 2027
    Table 2. Major Manufacturers of Methylnaltrexone Bromide
    Table 3. Major Manufacturers of Lubiprostone
    Table 4. Major Manufacturers of Naloxegol
    Table 5. Major Manufacturers of Others
    Table 6. Global Opioid-Induced Constipation Market Size Growth by Application (US$ Million): 2021 VS 2027
    Table 7. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2021 VS 2027
    Table 8. Global Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
    Table 9. Global Opioid-Induced Constipation Sales Forecast by Region (2022-2027) & (K Units)
    Table 10. Global Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
    Table 11. Global Opioid-Induced Constipation Revenue Forecast by Region (2022-2027) & (US$ Million)
    Table 12. Global Opioid-Induced Constipation Sales by Manufacturer (2016-2021) & (K Units)
    Table 13. Global Opioid-Induced Constipation Sales Share by Manufacturer (2016-2021)
    Table 14. Opioid-Induced Constipation Revenue by Manufacturer (2016-2021) & (US$ Million)
    Table 15. Opioid-Induced Constipation Revenue Share by Manufacturer (2016-2021)
    Table 16. Key Manufacturers Opioid-Induced Constipation Price (2016-2021) & (USD/Unit)
    Table 17. Ranking of Global Top Opioid-Induced Constipation Manufacturers by Revenue (US$ Million) in 2020
    Table 18. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
    Table 19. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2020)
    Table 20. Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution and Headquarters
    Table 21. Manufacturers Opioid-Induced Constipation Product Type
    Table 22. Date of International Manufacturers Enter into Opioid-Induced Constipation Market
    Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 24. Takeda Pharmaceuticals Corporation Information
    Table 25. Takeda Pharmaceuticals Description and Business Overview
    Table 26. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 27. Takeda Pharmaceuticals Opioid-Induced Constipation Product
    Table 28. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 29. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 30. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 31. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel
    Table 32. Takeda Pharmaceuticals Recent Development
    Table 33. Bayer Corporation Information
    Table 34. Bayer Description and Business Overview
    Table 35. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 36. Bayer Opioid-Induced Constipation Product
    Table 37. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 38. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 39. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 40. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel
    Table 41. Bayer Recent Development
    Table 42. Sanofi Corporation Information
    Table 43. Sanofi Description and Business Overview
    Table 44. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 45. Sanofi Opioid-Induced Constipation Product
    Table 46. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 47. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 48. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 49. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel
    Table 50. Sanofi Recent Development
    Table 51. Mallinckrodt Corporation Information
    Table 52. Mallinckrodt Description and Business Overview
    Table 53. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 54. Mallinckrodt Opioid-Induced Constipation Product
    Table 55. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 56. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 57. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 58. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel
    Table 59. Mallinckrodt Recent Development
    Table 60. Salix (Bausch Health) Corporation Information
    Table 61. Salix (Bausch Health) Description and Business Overview
    Table 62. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 63. Salix (Bausch Health) Opioid-Induced Constipation Product
    Table 64. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 65. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 66. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 67. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel
    Table 68. Salix (Bausch Health) Recent Development
    Table 69. AstraZeneca Corporation Information
    Table 70. AstraZeneca Description and Business Overview
    Table 71. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 72. AstraZeneca Opioid-Induced Constipation Product
    Table 73. AstraZeneca Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 74. AstraZeneca Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 75. AstraZeneca Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 76. AstraZeneca Recent Development
    Table 77. Progenics Pharmaceuticals Corporation Information
    Table 78. Progenics Pharmaceuticals Description and Business Overview
    Table 79. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 80. Progenics Pharmaceuticals Opioid-Induced Constipation Product
    Table 81. Progenics Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 82. Progenics Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 83. Progenics Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 84. Progenics Pharmaceuticals Recent Development
    Table 85. Purdue Pharm Corporation Information
    Table 86. Purdue Pharm Description and Business Overview
    Table 87. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 88. Purdue Pharm Opioid-Induced Constipation Product
    Table 89. Purdue Pharm Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 90. Purdue Pharm Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 91. Purdue Pharm Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 92. Purdue Pharm Recent Development
    Table 93. Nektar Therapeutics Corporation Information
    Table 94. Nektar Therapeutics Description and Business Overview
    Table 95. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 96. Nektar Therapeutics Opioid-Induced Constipation Product
    Table 97. Nektar Therapeutics Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 98. Nektar Therapeutics Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 99. Nektar Therapeutics Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 100. Nektar Therapeutics Recent Development
    Table 101. Daiichi Sankyo Corporation Information
    Table 102. Daiichi Sankyo Description and Business Overview
    Table 103. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 104. Daiichi Sankyo Opioid-Induced Constipation Product
    Table 105. Daiichi Sankyo Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 106. Daiichi Sankyo Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 107. Daiichi Sankyo Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 108. Daiichi Sankyo Recent Development
    Table 109. Prestige Corporation Information
    Table 110. Prestige Description and Business Overview
    Table 111. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 112. Prestige Opioid-Induced Constipation Product
    Table 113. Prestige Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 114. Prestige Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 115. Prestige Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 116. Prestige Recent Development
    Table 117. GSK Corporation Information
    Table 118. GSK Description and Business Overview
    Table 119. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 120. GSK Opioid-Induced Constipation Product
    Table 121. GSK Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 122. GSK Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 123. GSK Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 124. GSK Recent Development
    Table 125. Shionogi Corporation Information
    Table 126. Shionogi Description and Business Overview
    Table 127. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 128. Shionogi Opioid-Induced Constipation Product
    Table 129. Shionogi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product
    Table 130. Shionogi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application
    Table 131. Shionogi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area
    Table 132. Shionogi Recent Development
    Table 133. Global Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
    Table 134. Global Opioid-Induced Constipation Sales Forecast by Type (2022-2027) & (K Units)
    Table 135. Global Opioid-Induced Constipation Revenue by Type (2016-2021) & (US$ Million)
    Table 136. Global Opioid-Induced Constipation Revenue Forecast by Type (2022-2027) & (US$ Million)
    Table 137. Global Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
    Table 138. Global Opioid-Induced Constipation Sales Forecast by Application (2022-2027) & (K Units)
    Table 139. Global Opioid-Induced Constipation Revenue by Application (2016-2021) & (US$ Million)
    Table 140. Global Opioid-Induced Constipation Revenue Forecast by Application (2022-2027) & (US$ Million)
    Table 141. North America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
    Table 142. North America Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
    Table 143. North America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
    Table 144. North America Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
    Table 145. North America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
    Table 146. North America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
    Table 147. Asia-Pacific Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
    Table 148. Asia-Pacific Opioid-Induced Constipation Sales by Region (2022-2027) & (K Units)
    Table 149. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2016-2027) & (US$ Million)
    Table 150. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2022-2027) & (US$ Million)
    Table 151. Asia-Pacific Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
    Table 152. Asia-Pacific Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
    Table 153. Europe Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
    Table 154. Europe Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
    Table 155. Europe Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
    Table 156. Europe Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
    Table 157. Europe Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
    Table 158. Europe Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
    Table 159. Latin America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
    Table 160. Latin America Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
    Table 161. Latin America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
    Table 162. Latin America Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
    Table 163. Latin America Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
    Table 164. Latin America Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
    Table 165. Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
    Table 166. Middle East and Africa Opioid-Induced Constipation Sales by Country (2022-2027) & (K Units)
    Table 167. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
    Table 168. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2022-2027) & (US$ Million)
    Table 169. Middle East and Africa Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)
    Table 170. Middle East and Africa Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)
    Table 171. Opioid-Induced Constipation Key Raw Materials, Industry Status and Trend
    Table 172. Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers
    Table 173. Opioid-Induced Constipation Clients Status and Trend
    Table 174. Opioid-Induced Constipation Typical Clients
    Table 175. Opioid-Induced Constipation Distributors
    Table 176. Key Drivers: Impact Analysis (2022-2027)
    Table 177. Opioid-Induced Constipation Market Drivers
    Table 178. Opioid-Induced Constipation Market Opportunities
    Table 179. Opioid-Induced Constipation Market Challenges
    Table 180. Opioid-Induced Constipation Market Restraints
    Table 181. Opioid-Induced Constipation Porter’s Five Forces Analysis
    Table 182. Research Programs/Design for This Report
    Table 183. Key Data Information from Secondary Sources
    Table 184. Key Data Information from Primary Sources
List of Figures
    Figure 1. Opioid-Induced Constipation Product Picture
    Figure 2. Global Opioid-Induced Constipation Sales Market Share by Type in 2021 & 2027
    Figure 3. Methylnaltrexone Bromide Product Picture
    Figure 4. Lubiprostone Product Picture
    Figure 5. Naloxegol Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Opioid-Induced Constipation Sales Market Share by Application in 2021 & 2027
    Figure 8. Hospital Examples
    Figure 9. Pharmacy Examples
    Figure 10. Other Examples
    Figure 11. Opioid-Induced Constipation Report Years Considered
    Figure 12. Global Opioid-Induced Constipation Market Size, (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Opioid-Induced Constipation Market Size 2016-2027 (US$ Million)
    Figure 14. Global Opioid-Induced Constipation Sales 2016-2027 (K Units)
    Figure 15. Global Opioid-Induced Constipation Market Size Market Share by Region: 2021 Versus 2027
    Figure 16. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2016-2027)
    Figure 17. Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2027)
    Figure 18. Global Opioid-Induced Constipation Sales Share by Manufacturer in 2020
    Figure 19. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
    Figure 20. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2016-2027)
    Figure 21. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2016-2027)
    Figure 22. Opioid-Induced Constipation Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
    Figure 23. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2016-2027)
    Figure 24. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2016-2027)
    Figure 25. Opioid-Induced Constipation Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
    Figure 26. North America Opioid-Induced Constipation Revenue 2016-2027 (US$ Million)
    Figure 27. North America Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
    Figure 28. North America Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
    Figure 29. Asia-Pacific Opioid-Induced Constipation Revenue 2016-2027 (US$ Million)
    Figure 30. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Region (2016-2027)
    Figure 31. Asia-Pacific Opioid-Induced Constipation Revenue Market Share by Region (2016-2027)
    Figure 32. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
    Figure 33. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
    Figure 34. Europe Opioid-Induced Constipation Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 35. Europe Opioid-Induced Constipation Sales Market Share by Country (2016-2027)
    Figure 36. Europe Opioid-Induced Constipation Revenue Market Share by Country (2016-2027)
    Figure 37. Europe Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
    Figure 38. Europe Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
    Figure 39. Latin America Opioid-Induced Constipation Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 40. Latin America Opioid-Induced Constipation Sales Market Share by Country (2016-2027)
    Figure 41. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
    Figure 42. Latin America Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
    Figure 43. Latin America Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
    Figure 44. Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 45. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2016-2027)
    Figure 46. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2016-2027)
    Figure 47. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
    Figure 48. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
    Figure 49. Opioid-Induced Constipation Supply Chain (Upstream and Downstream Market)
    Figure 50. Global Production Market Share of Opioid-Induced Constipation Raw Materials by Region in 2020
    Figure 51. Opioid-Induced Constipation Distribution Channels
    Figure 52. Global Opioid-Induced Constipation Percentage 2016-2027: Indirect Sales VS Direct Sales
    Figure 53. Global Opioid-Induced Constipation Percentage 2016-2027: Online Sales VS Offline Sales
    Figure 54. Porter's Five Forces Analysis
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
    Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$5900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$8850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$11800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Lukasiewicz Research Network

RELATED REPORTS

Global Nebivolol Hydrochloride Market Insights Forecast to 2028
Global Nebivolol Hydrochloride Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-12T7632
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Nefopam Hydrochloride Market Insights Forecast to 2028
Global Nefopam Hydrochloride Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-36U7490
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Naratriptan Hydrochloride Market Insights Forecast to 2028
Global Naratriptan Hydrochloride Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-14C7602
Fri May 13 00:00:00 UTC 2022

Add to Cart

Global Nelfinavir Market Insights Forecast to 2028
Global Nelfinavir Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-25I7469
Fri May 13 00:00:00 UTC 2022

Add to Cart